Lumida
/INSP
⌘K
Inspire Medical Systems Inc

Inspire Medical Systems Inc

INSP
$73.00USD↑+7.16%+4.88 today

MARKET CAP

2.1B

P/E (TTM)

16.6x

FWD P/E

—

DAY RANGE

$70 – $75

52W RANGE

$39
$147

AI Summary

Stalk
Buy NowMedium

INSP is in a Stage 2 advancing structure with a recent Momentum Breakout and active Lockout Rally indicating overwhelming demand. Although RSI is in overbought territory and price is extended above EMAs, Lockout Rally dynamics justify immediate entry to participate in further upside. Medium-term bias is bullish, while the long-term trend remains bearish below the 200 SMA. We buy now to capture continuation, provided price holds above the 9/20 EMA cluster.

  • ↑Q4 2025 revenue reached $269M, up 12% YoY; full-year $912M, +14% YoY.
  • ↑Over 90% of treatment centers trained on Inspire 5, boosting procedure success.
  • ↓Coding and WISER program challenges trimmed Q2 results by ~$40M.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Inspire Medical Systems, Inc. (NYSE: INSP) operates in the medical device sector, specializing in innovative therapies for obstructive sleep apnea (OSA) through its hypoglossal nerve stimulation technology. The company is positioned as a leader in this niche market, capitalizing on advancements in sleep health awareness and treatment effectiveness. With the recent launch of the Inspire 5 system, Inspire aims to enhance patient outcomes and streamline surgical procedures, thereby solidifying its competitive standing in the rapidly evolving healthcare landscape.

Bull says

  • ↑Q4 2025 revenue reached $269M, up 12% YoY; full-year $912M, +14% YoY.
  • ↑Over 90% of treatment centers trained on Inspire 5, boosting procedure success.
  • ↑Project Horizon initiative projected to fund $30M in annual growth investment.
  • ↑International markets to expand post-countrywide reimbursement in Europe.
  • ↑Clinical studies show shorter surgeries and higher success, aiding adoption.
  • ↑High liquidity and positive revisions signal stability for growth initiatives.

Bear says

  • ↓Coding and WISER program challenges trimmed Q2 results by ~$40M.
  • ↓Operating expenses rose 17% YoY, risking margin compression.
  • ↓Full-year revenue guidance reduced to $835M–$875M from $900M.
  • ↓Negative momentum and rising short interest reflect investor skepticism.
  • ↓Emerging GLP-1 therapies may divert patients from Inspire treatments.
  • ↓Regulatory and reimbursement uncertainty could delay adoption recovery.

Investment themes with INSP

Medical Devices↓ -0.50%

Devices and instruments for medical treatment

ISRG · ABT · SYK

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 09-01-2026neutral

Transcript signals

Bull points

  • Total revenue for the quarter was $217.1 million, an 11% increase from the $195.9 million generated in the second quarter of 2024.
  • U.S. revenue in the quarter was $207.2 million, an increase of 10% from the $187.8 million in the prior year period.
  • Revenue outside the U.S. was $9.9 million, which was a 23% increase year over year.

Bear points

  • Operating loss for the quarter totaled $3.3 million compared to an operating income of $5.1 million in the prior year period.
  • Net loss for the quarter was $3.6 million compared to a net income of $9.8 million in the prior year period.
  • we now expect full year revenue to be in the range of $900 to $910 million, down from $940 to $955 million, representing an annual increase of 12% to 13% compared to full year 2024 revenue. We expect diluted net income for the full year 2025 will be 40 to 50 cents per share, a decrease from our previous range of 220 to 230 per share, which is primarily due to the revised revenue guidance and to a lesser extent the planned increase in patient marketing costs for the second half of the year.
Read full transcript analysis ›